Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer

Area of Science:

• Nuclear Medicine
• Oncology
• Radiochemistry

Background:

• Positron emission tomography (PET) tracers like (18)F-FDG are crucial for non-small cell lung cancer (NSCLC) diagnosis and management.
• Hypoxia imaging tracers, such as (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) ((62)Cu-ATSM), offer complementary information on tumor microenvironment.
• Understanding the differential uptake and distribution of these tracers is vital for accurate staging and treatment selection.

Purpose of the Study:

• To compare the intratumoral uptake and distribution patterns of (62)Cu-ATSM and (18)F-FDG in patients with pathohistologically distinct lung cancer types.
• To investigate how tracer distribution correlates with squamous cell carcinoma (SCC) and adenocarcinoma subtypes.
• To assess the potential of these PET tracers in differentiating regional biologic characteristics within lung tumors.

Main Methods:

• Eight SCC and five adenocarcinoma patients underwent both (62)Cu-ATSM and (18)F-FDG PET scans within a week.
• Standardized uptake values (SUVs) were quantified in regions of interest drawn on tumor lesions.
• Regression analysis was used to compare tracer SUVs, and slopes were compared between SCC and adenocarcinoma groups.

Main Results:

• (62)Cu-ATSM uptake was generally lower than (18)F-FDG uptake in both cancer types.
• SCC tumors exhibited spatial mismatching: high (62)Cu-ATSM and low (18)F-FDG peripherally, and vice versa centrally.
• Adenocarcinoma tumors showed similar spatial distribution for both tracers, with a significant difference in regression slopes between SCC and adenocarcinoma (P < 0.001).

Conclusions:

• Intratumoral distribution of (62)Cu-ATSM and (18)F-FDG differs significantly between SCC and adenocarcinoma.
• This suggests that regions of high glucose metabolism and hypoxia vary with lung cancer pathohistology.
• Identifying regional tumor characteristics like hypoxia and metabolism is crucial for NSCLC diagnosis and therapy planning.